{"gene":"ENO2","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1980,"finding":"Neuron-specific enolase (NSE/ENO2) is expressed specifically in neurons (not glial cells) of mature brain, with levels very low in embryonic brain and increasing coincident with morphological and functional neuronal maturation, consistent with a developmental switch from non-neuronal enolase (NNE/ENO1) to NSE during neuronal differentiation.","method":"Radioimmunoassay of isoenzyme content during rat brain development, with regional and temporal profiling","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative isoenzyme measurement across developmental stages, single lab but systematic temporal and regional analysis","pmids":["6769532"],"is_preprint":false},{"year":1986,"finding":"In yeast, ENO2 contains two upstream activation site (UAS) cis-acting regulatory regions immediately flanking position 461 bp upstream of the transcriptional initiation site; either UAS alone is sufficient for glucose-dependent induction and normal expression on gluconeogenic carbon sources, but deletion of both abolishes expression. Small deletions within the UAS permit normal expression on gluconeogenic sources but abolish glucose-dependent induction, identifying a specific cis-acting sequence mediating glucose induction.","method":"Deletion mapping of ENO2 5' flanking sequences fused to ENO1 coding sequences; integration at ENO1 locus; expression monitored on glucose vs. gluconeogenic carbon sources","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vivo deletion mapping with multiple mutant constructs and orthogonal carbon source conditions, replicated across multiple deletion alleles","pmids":["3537717"],"is_preprint":false},{"year":1990,"finding":"Three distinct protein-binding sites exist within the upstream activation sites of yeast ENO2: RAP1 protein binds sequences overlapping UAS1; ABFI (autonomously replicating sequence-binding factor) binds sequences within the UAS2 element; and EBF1 (enolase-binding factor) binds sequences overlapping UAS2 of ENO1. The ABFI-binding site in ENO2 overlaps sequences required for UAS2 activity and for repression of ENO2 in gcr1 null mutants, indicating ABFI, like RAP1, can mediate both positive and negative regulation.","method":"DNase I footprinting, gel mobility shift assays, deletion analysis in vivo, identification of RAP1 and ABFI by protein purification and binding","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical and genetic methods (footprinting, EMSA, in vivo expression) in single rigorous study","pmids":["2201905"],"is_preprint":false},{"year":1990,"finding":"In yeast, ABFI is identified as the major protein binding the UAS/repression site of ENO2; deletion of this site permits wild-type ENO2 expression in gcr1 null strains, demonstrating that ABFI-bound sequences are required both for transcriptional activation in wild-type and for GCR1-dependent repression; the UAS/repression site alone is sufficient for transcriptional activation but not sufficient for repression in gcr1 backgrounds.","method":"Deletion mapping in gcr1 null strains, gel mobility shift assays identifying ABFI, in vivo transcription assays with UAS-less promoter cassettes","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic epistasis (gcr1 null) combined with protein-DNA binding identification and in vivo transcription assays","pmids":["2201904"],"is_preprint":false},{"year":1990,"finding":"Human ENO2 gene localizes to chromosome region 12p13, as determined by in situ hybridization; additional minor hybridization to 1p36 likely reflects cross-hybridization to ENO1, and a signal at chromosome 17 may represent another enolase family member.","method":"In situ hybridization of human ENO2 cDNA to chromosomes","journal":"Cytogenetics and cell genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, single method (in situ hybridization), no functional validation","pmids":["2249478"],"is_preprint":false},{"year":1990,"finding":"NSE immunoreactivity and NSE mRNA both increase in rat cerebellar Purkinje cells from postnatal day 3 to 9, but thereafter NSE-immunoreactive Purkinje cell somata decrease in number while mRNA remains detectable in somata through adulthood, with distinct NSE immunoreactivity remaining in Purkinje cell axons. This discrepancy suggests negative translational control and/or axoplasmic transport of NSE protein.","method":"Immunohistochemistry and in situ hybridization in rat cerebellum across postnatal development","journal":"Brain research. Developmental brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (IHC and ISH) systematically applied across developmental time points, single lab","pmids":["2350885"],"is_preprint":false},{"year":1987,"finding":"NSE mRNA is expressed specifically in neurons (not glia or liver cells) in human brain, as detected by in situ hybridization with probes from the 3' untranslated region of ENO2 in autopsy brain samples from controls and Alzheimer's disease patients.","method":"In situ hybridization with biotinylated DNA and RNA probes in human autopsy brain tissue","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single method (ISH), single lab, no functional manipulation","pmids":["3587757"],"is_preprint":false},{"year":1993,"finding":"A 60-bp ENO2 sequence is sufficient to confer high-level, GCR1-dependent transcriptional activation; it can be subdivided into a 30-bp region containing overlapping RAP1 and GCR1 binding sites (not sufficient alone for activation) and a 30-bp region with a novel GCR1-independent enhancer element. The overlapping ABFI/RAP1 sites upstream function together with the GCR1/RAP1-binding sequences to stage transcriptional activation.","method":"Enhancerless CYC1 promoter fusion assay, deletion mapping, in vivo transcription quantification in gcr1 null strains","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic epistasis with gcr1 null, multiple deletion constructs, in vivo expression assays with heterologous promoter system","pmids":["8455635"],"is_preprint":false},{"year":2009,"finding":"p19(ras), an alternative splicing product of c-H-ras, physically interacts with NSE (ENO2) and inhibits its enzymatic activity; co-immunoprecipitation confirmed the interaction both endogenously and in overexpression systems; p19(ras) also inhibits enolase alpha activity in vitro. The interaction suppresses lung cancer cell proliferation that was increased by NSE.","method":"Yeast two-hybrid identification of NSE as p19(ras)-binding partner; co-immunoprecipitation in endogenous and overexpression systems; in vitro enzymatic activity assay; cell proliferation assay in H1299 cells","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus in vitro activity assay plus cell proliferation, single lab, multiple orthogonal methods","pmids":["19713034"],"is_preprint":false},{"year":2011,"finding":"ENO2 (NSE) is upregulated in GBM cells under cellular stress conditions (serum starvation and hypoxia); NSE knockdown by siRNA reduces GBM cell migration and sensitizes cells to hypoxia, radiotherapy, and temozolomide, establishing a functional role for ENO2 in stress adaptation and resistance in glioblastoma cells.","method":"qPCR under different culture conditions; siRNA knockdown of NSE; Electric cell-substrate impedance sensing (ECIS) for migration; MTS viability assay after irradiation and temozolomide","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean siRNA knockdown with multiple phenotypic readouts (migration, viability, drug sensitivity), single lab","pmids":["22185371"],"is_preprint":false},{"year":2011,"finding":"ENO2 (NSE) expressed in MCF-10A breast epithelial cells transformed by arsenite (As+3) or cadmium (Cd+2) localizes to both cytoplasm and nucleus, whereas ENO1 localizes only to cytoplasm; cytoplasmic ENO2 co-localizes with ENO1. Both acute and chronic exposure to As+3 or Cd+2 significantly induces ENO2 expression with no effect on ENO1 expression.","method":"Immunofluorescence localization; Western blot; acute and chronic metal exposure of MCF-10A cells","journal":"Cancer cell international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single set of methods, localization shown but functional consequence of nuclear ENO2 not established","pmids":["22098917"],"is_preprint":false},{"year":2018,"finding":"ENO2 promotes ALL cell growth, glycolysis, and glucocorticoid resistance; mechanistically, ENO2 upregulates glycolysis-related genes and enhances AKT activity with subsequent GSK-3β phosphorylation, inducing cell proliferation and glycolysis. Silencing ENO2 with shRNAs inhibits these effects, and combined ENO2 silencing plus 2-deoxyglucose synergistically inhibits leukemia cell survival.","method":"shRNA knockdown; Cell Counting Kit-8 proliferation assay; glucose consumption assay; Western blotting; in vivo tumorigenesis in NOD/SCID mice","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA knockdown with multiple orthogonal readouts (proliferation, glycolysis, in vivo), single lab","pmids":["29689546"],"is_preprint":false},{"year":2019,"finding":"NSE (ENO2) from DLBCL lymphoma cells is transferred to macrophages via exosomes, whereupon NSE enhances nuclear p50 translocation and suppresses classical NF-κB activity in macrophages, promoting M2 polarization and migration of macrophages, thereby promoting lymphoma progression in vitro and in vivo.","method":"Functional overexpression/knockdown studies in lymphoma cell lines; exosome isolation; macrophage co-culture; in vitro and in vivo (mouse) experiments; Western blotting for p50 nuclear translocation","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway (NF-κB) identified with nuclear translocation assay plus in vivo validation, single lab","pmids":["31191019"],"is_preprint":false},{"year":2019,"finding":"SIRT1 physically binds NSE (ENO2) and PKM in rat brain tissue; modulation of SIRT1 enzymatic activity (by agonist SRT1720 or antagonist EX527, or by SIRT1 overexpression/knockout) significantly affects the acetylation level of endogenous NSE, and changes in NSE acetylation affect its catalytic glycolytic activity.","method":"GST pull-down followed by LC-MS/MS identification; co-immunoprecipitation; SIRT1 agonist/antagonist treatment; SIRT1 overexpression and knockout; measurement of NSE catalytic activity","journal":"Biochimica et biophysica acta. Proteins and proteomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pull-down + Co-IP + functional activity assay + genetic manipulation, single lab, multiple orthogonal methods","pmids":["31202897"],"is_preprint":false},{"year":2021,"finding":"ENO2 promotes cell proliferation and glycolysis in HNSCC partially by controlling PKM2 protein stability and nuclear translocation: loss of ENO2 promotes PKM2 degradation via the ubiquitin-proteasome pathway and prevents nuclear translocation of PKM2 by inactivating AKT signaling, blocking PKM2-mediated glycolytic flux and CCND1-associated cell cycle progression.","method":"qRT-PCR, Western blotting, immunofluorescence, immunoprecipitation, ChIP-PCR, ATP and glucose level assays; ENO2 inhibitor AP-III-a4 in preclinical mouse model","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (IP, ChIP, IHC, metabolic assays, in vivo), single lab","pmids":["36588153"],"is_preprint":false},{"year":2022,"finding":"ENO2 promotes colorectal cancer cell migration and invasion through interaction with lncRNA CYTOR; this interaction does not depend on glycolysis regulation. CYTOR mediates ENO2 binding to LATS1, competitively inhibiting YAP1 phosphorylation and triggering epithelial-mesenchymal transition (EMT).","method":"ENO2 knockdown and overexpression; migration/invasion assays; co-immunoprecipitation of ENO2-CYTOR-LATS1 complex; YAP1 phosphorylation analysis; TCGA/GEO database analysis; 184 local CRC samples","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrating three-component complex, loss/gain of function with phenotypic readouts, single lab","pmids":["35954207"],"is_preprint":false},{"year":2023,"finding":"ENO2-derived metabolite phosphoenolpyruvate (PEP) selectively inhibits HDAC1 activity, increasing acetylation of β-catenin and activating the β-catenin pathway in colorectal cancer, driving resistance to antiangiogenic therapy. ENO2 overexpression induces neuroendocrine differentiation and promotes malignant behavior; ENO2 inhibitors (AP-III-a4 or POMHEX) synergize with antiangiogenic drugs in vitro and in drug-resistant CRC xenograft mouse models.","method":"CRC mouse models and human participant samples; in vitro HDAC1 activity assay with PEP; β-catenin acetylation and pathway analysis; ENO2 inhibitor treatment in vivo","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic assay demonstrating PEP inhibits HDAC1, combined with in vivo mouse models and human participant data, multiple orthogonal methods","pmids":["37667133"],"is_preprint":false},{"year":2023,"finding":"ENO2 and ALDOC are required for anchorage-independent 3D tumor spheroid growth across lung and breast cancer cell lines; siRNA-mediated knockdown of ENO2 significantly reduces lactate production, viability, and spheroid size in H460, HCC827, MCF7, and T47D cell lines, demonstrating that ENO2-driven glycolytic flux supports anchorage-independent survival.","method":"siRNA knockdown; multi-omics (transcriptomics, proteomics, metabolomics); lactate production assay; viability and spheroid size measurement in 3D culture","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown across four cell lines with metabolic and viability readouts, multi-omics validation, single lab","pmids":["36945054"],"is_preprint":false},{"year":2024,"finding":"DLBCL-derived exosomal ENO2 is assimilated by macrophages and modulates macrophage polarization (increased M2, decreased M1) through reprogramming glycolysis via the GSK3β/β-catenin/c-Myc signaling pathway, thereby promoting DLBCL cell proliferation, migration, and invasion in vitro and in vivo.","method":"Exosome isolation and uptake assays; in vitro and in vivo macrophage polarization experiments; pathway inhibition assays; bioinformatics analysis","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — exosome uptake demonstrated with in vitro and in vivo validation, pathway mechanistic dissection, single lab","pmids":["38250157"],"is_preprint":false},{"year":2021,"finding":"ENO2 expression in trophoblasts is regulated epigenetically: the histone demethylase KDM3A binds the ENO2 locus and reduces its methylation, promoting ENO2 expression; let-7d miRNA directly targets KDM3A to suppress it, resulting in increased ENO2 methylation and reduced ENO2 expression. Overexpression of let-7d suppresses trophoblast proliferation, migration, and invasion, which can be rescued by restoring ENO2 expression.","method":"Dual luciferase reporter assay for let-7d/KDM3A and let-7d/ENO2 interactions; ChIP experiment identifying KDM3A methylation of ENO2 locus; gain/loss-of-function; in vivo PE rat model","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for epigenetic regulation + luciferase reporter + in vivo rat model, single lab, multiple orthogonal methods","pmids":["34350711"],"is_preprint":false},{"year":2022,"finding":"E2F1 transcription factor upregulates ENO2 expression to promote the Warburg effect (increased glucose uptake, lactate production, ATP generation) and cell viability and invasion in Ewing sarcoma; altering E2F1 expression correspondingly changes ENO2 levels and aerobic glycolysis.","method":"E2F1 overexpression/knockdown; glucose uptake, lactate production, ATP generation assays; cell viability and invasion assays","journal":"Molecular medicine reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, indirect evidence that E2F1 regulates ENO2, mechanism of transcriptional regulation not directly demonstrated (no ChIP or promoter assay shown)","pmids":["35621141"],"is_preprint":false},{"year":2025,"finding":"FGF2 stimulation of human retinal microvascular endothelial cells upregulates ENO2 protein levels and glycolytic activity; ENO2 knockdown diminishes glycolytic activity and impairs angiogenic processes (tube formation, migration, proliferation). The ENO2 inhibitor AP-III-a4 alleviates retinal neovascularization in the oxygen-induced retinopathy mouse model in vivo.","method":"Data-independent acquisition proteomics; qRT-PCR and Western blot; siRNA knockdown; transwell/EdU/tube formation assays; ENO2 inhibitor treatment in OIR mouse model; immunofluorescence","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics + knockdown + in vivo inhibitor, single lab, multiple orthogonal methods","pmids":["39854009"],"is_preprint":false}],"current_model":"ENO2 (NSE) is a neuron-specific glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate (PEP); beyond glycolysis, ENO2-derived PEP functions as an endogenous inhibitor of HDAC1 to activate β-catenin signaling, ENO2 controls PKM2 stability and nuclear translocation via AKT-ubiquitin pathways, it is deacetylated and regulated by SIRT1, it can be transferred via exosomes to reprogram macrophage polarization through NF-κB and GSK3β/β-catenin/c-Myc pathways, its expression is regulated by transcription factors RAP1/ABFI/GCR1 (in yeast) and by epigenetic methylation via the let-7d/KDM3A axis (in mammals), and its activity is inhibited by physical interaction with p19(ras)."},"narrative":{"mechanistic_narrative":"ENO2 (neuron-specific enolase, NSE) is a glycolytic enzyme whose expression switches on during neuronal maturation, replacing the non-neuronal isoform as neurons morphologically and functionally differentiate [PMID:6769532, PMID:3587757]. Beyond its housekeeping role in catalyzing 2-phosphoglycerate to phosphoenolpyruvate (PEP), ENO2 functions as a driver of aerobic glycolysis (the Warburg effect) that supports proliferation, migration, and stress adaptation across diverse cancers, including glioblastoma, acute lymphoblastic leukemia, head and neck and colorectal carcinomas, and in 3D anchorage-independent growth [PMID:22185371, PMID:29689546, PMID:36588153, PMID:36945054]. A key non-canonical mechanism is metabolite-mediated signaling: ENO2-derived PEP selectively inhibits HDAC1, increasing β-catenin acetylation and activating β-catenin signaling to drive neuroendocrine differentiation and antiangiogenic therapy resistance [PMID:37667133]. ENO2 additionally couples to AKT/GSK-3β signaling to promote glycolysis and glucocorticoid resistance, and controls PKM2 protein stability and nuclear translocation via the ubiquitin-proteasome and AKT pathways, linking it to CCND1-associated cell cycle progression [PMID:29689546, PMID:36588153]. Through protein and RNA interactions ENO2 also acts independently of its catalytic function—binding lncRNA CYTOR and LATS1 to inhibit YAP1 phosphorylation and trigger EMT [PMID:35954207]—and can be exported in exosomes to reprogram macrophage polarization toward an M2 state via NF-κB and GSK3β/β-catenin/c-Myc pathways [PMID:31191019, PMID:38250157]. ENO2 enzymatic activity is regulated post-translationally by SIRT1-dependent deacetylation [PMID:31202897] and inhibited by physical interaction with the c-H-ras splice product p19(ras) [PMID:19713034]. Its expression is controlled transcriptionally and epigenetically—by the let-7d/KDM3A demethylation axis in trophoblasts [PMID:34350711] and, in yeast, by RAP1/ABFI/GCR1 acting through defined upstream activation sites [PMID:3537717, PMID:2201905, PMID:8455635].","teleology":[{"year":1980,"claim":"Established that ENO2 is the neuronally-restricted enolase isoform whose induction tracks neuronal differentiation, defining it as a maturation marker distinct from the non-neuronal isoform.","evidence":"Radioimmunoassay of enolase isoenzymes across rat brain development with regional/temporal profiling, confirmed by in situ hybridization in human brain","pmids":["6769532","3587757"],"confidence":"Medium","gaps":["Does not establish the molecular trigger of the NNE-to-NSE switch","Functional consequence of neuron-restricted expression not addressed"]},{"year":1990,"claim":"Dissected the cis- and trans-regulatory logic of yeast ENO2 transcription, showing overlapping RAP1/ABFI/GCR1 binding sites within upstream activation sequences mediate both glucose-dependent activation and GCR1-dependent repression.","evidence":"Deletion mapping of 5' flanking sequences, DNase I footprinting, EMSA, and in vivo expression assays in gcr1 null strains on glucose vs. gluconeogenic carbon sources","pmids":["3537717","2201905","2201904","8455635"],"confidence":"High","gaps":["Regulatory logic established in yeast, not mapped to mammalian ENO2 promoter","Does not connect transcriptional control to enzyme function"]},{"year":2009,"claim":"Identified the first physical regulator of mammalian ENO2 activity, showing p19(ras) binds and inhibits NSE enzymatic activity to suppress tumor cell proliferation.","evidence":"Yeast two-hybrid, reciprocal co-immunoprecipitation (endogenous and overexpression), in vitro enzyme activity assay, and proliferation assays in H1299 cells","pmids":["19713034"],"confidence":"Medium","gaps":["Structural basis of the inhibitory interaction not defined","Physiological contexts where p19(ras) regulates ENO2 not established"]},{"year":2011,"claim":"Demonstrated a functional pro-survival role for ENO2 in cancer, linking its stress-induced upregulation to migration and therapy resistance.","evidence":"siRNA knockdown in glioblastoma cells with migration, viability, and drug/radiation sensitivity readouts under hypoxia and serum starvation; nuclear/cytoplasmic localization in transformed breast epithelial cells","pmids":["22185371","22098917"],"confidence":"Medium","gaps":["Mechanism linking ENO2 to resistance not resolved at this stage","Functional significance of nuclear ENO2 localization not established"]},{"year":2018,"claim":"Connected ENO2 to oncogenic signaling, showing it activates AKT/GSK-3β to drive glycolysis, proliferation, and glucocorticoid resistance.","evidence":"shRNA knockdown, proliferation and glucose consumption assays, Western blotting, and in vivo tumorigenesis in NOD/SCID mice, with 2-deoxyglucose combination","pmids":["29689546"],"confidence":"Medium","gaps":["Whether ENO2 acts on AKT signaling enzymatically or non-enzymatically not distinguished","Direct AKT-pathway interaction partner not identified"]},{"year":2019,"claim":"Revealed ENO2 as both a post-translationally regulated enzyme and an intercellular signaling molecule—deacetylated by SIRT1 to control catalytic activity, and exported via exosomes to reprogram macrophages through NF-κB.","evidence":"GST pull-down/LC-MS/MS and Co-IP for SIRT1 binding with acetylation and activity assays; exosome isolation, macrophage co-culture, and p50 nuclear translocation assays in lymphoma models in vitro and in vivo","pmids":["31202897","31191019"],"confidence":"Medium","gaps":["Specific acetylated lysine residues controlling activity not mapped","Mechanism of ENO2 packaging into exosomes unknown"]},{"year":2021,"claim":"Defined an epigenetic regulatory axis controlling ENO2 expression, with KDM3A demethylating the locus to activate it and let-7d suppressing KDM3A to silence it.","evidence":"Dual luciferase reporter assays, ChIP for KDM3A at the ENO2 locus, gain/loss-of-function, and an in vivo preeclampsia rat model in trophoblasts","pmids":["34350711"],"confidence":"Medium","gaps":["Whether this axis operates outside trophoblasts not tested","Direct demethylase enzymatic action on ENO2 chromatin not biochemically isolated"]},{"year":2022,"claim":"Uncovered a glycolysis-independent function of ENO2 in metastasis, acting as a scaffold with lncRNA CYTOR and LATS1 to inhibit YAP1 phosphorylation and drive EMT.","evidence":"Knockdown/overexpression with migration/invasion assays, Co-IP of the ENO2-CYTOR-LATS1 complex, YAP1 phosphorylation analysis, and clinical CRC sample correlation","pmids":["35954207"],"confidence":"Medium","gaps":["Structural basis of the ternary complex not resolved","Whether RNA binding is direct or bridged by other factors unclear"]},{"year":2023,"claim":"Established the landmark non-canonical mechanism in which ENO2's metabolic product PEP acts as an endogenous HDAC1 inhibitor to activate β-catenin and drive neuroendocrine differentiation and therapy resistance, while confirming ENO2-driven glycolytic flux sustains anchorage-independent tumor growth.","evidence":"In vitro HDAC1 activity assay with PEP, β-catenin acetylation/pathway analysis, ENO2 inhibitor treatment in drug-resistant CRC xenografts and human samples; siRNA knockdown across four lung/breast lines with lactate and spheroid readouts","pmids":["37667133","36945054"],"confidence":"High","gaps":["Quantitative threshold of PEP needed to inhibit HDAC1 in vivo not defined","Whether PEP-HDAC1 inhibition operates in non-malignant neurons unknown"]},{"year":2024,"claim":"Refined the exosomal mechanism, showing transferred ENO2 reprograms macrophage glycolysis via the GSK3β/β-catenin/c-Myc pathway to promote M2 polarization and tumor progression.","evidence":"Exosome uptake assays, in vitro and in vivo macrophage polarization, pathway inhibition, and bioinformatics in DLBCL","pmids":["38250157"],"confidence":"Medium","gaps":["Whether transferred ENO2 acts enzymatically or as a signaling protein in recipient macrophages not resolved","Receptor/uptake route for ENO2-bearing exosomes unknown"]},{"year":2025,"claim":"Extended ENO2's glycolytic-angiogenic role beyond cancer, showing FGF2-induced ENO2 supports endothelial glycolysis and pathological retinal neovascularization.","evidence":"DIA proteomics, siRNA knockdown, tube formation/migration/proliferation assays, and ENO2 inhibitor (AP-III-a4) in the oxygen-induced retinopathy mouse model","pmids":["39854009"],"confidence":"Medium","gaps":["Mechanism linking FGF2 signaling to ENO2 induction not defined","Whether the PEP-HDAC1 axis contributes to angiogenesis not tested"]},{"year":null,"claim":"How ENO2's canonical glycolytic catalysis, its moonlighting metabolite-signaling (PEP-HDAC1), and its non-enzymatic scaffolding/exosomal roles are coordinated within a single cell—and whether these mechanisms operate in its native neuronal context—remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model integrating catalytic and non-catalytic functions","Native neuronal function beyond being a differentiation marker uncharacterized","No Mendelian disease link established in the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016829","term_label":"lyase activity","supporting_discovery_ids":[16,17]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[16]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[11,16,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,14,15,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,11,14,16]}],"complexes":[],"partners":["PKM2","SIRT1","P19(RAS)","LATS1","CYTOR","HDAC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09104","full_name":"Gamma-enolase","aliases":["2-phospho-D-glycerate hydro-lyase","Enolase 2","Neural enolase","Neuron-specific enolase","NSE"],"length_aa":434,"mass_kda":47.3,"function":"Enolase that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in glycolysis and the reverse reaction in gluconeogenesis (By similarity). Has neurotrophic and neuroprotective properties on a broad spectrum of central nervous system (CNS) neurons. Binds, in a calcium-dependent manner, to cultured neocortical neurons and promotes cell survival (By similarity)","subcellular_location":"Cytoplasm; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P09104/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ENO2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"AHCY","stoichiometry":0.2},{"gene":"ENO1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ENO2","total_profiled":1310},"omim":[{"mim_id":"617983","title":"MICROCEPHALY 21, PRIMARY, AUTOSOMAL RECESSIVE; MCPH21","url":"https://www.omim.org/entry/617983"},{"mim_id":"615638","title":"NON-SMC CONDENSIN I COMPLEX SUBUNIT D2; NCAPD2","url":"https://www.omim.org/entry/615638"},{"mim_id":"605475","title":"BAI1-ASSOCIATED PROTEIN 2; BAIAP2","url":"https://www.omim.org/entry/605475"},{"mim_id":"601007","title":"LEPTIN RECEPTOR; LEPR","url":"https://www.omim.org/entry/601007"},{"mim_id":"400022","title":"PROTOCADHERIN 11, Y-LINKED; PCDH11Y","url":"https://www.omim.org/entry/400022"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Plasma membrane","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":857.9},{"tissue":"retina","ntpm":1573.2}],"url":"https://www.proteinatlas.org/search/ENO2"},"hgnc":{"alias_symbol":["NSE"],"prev_symbol":[]},"alphafold":{"accession":"P09104","domains":[{"cath_id":"3.30.390.10","chopping":"4-127","consensus_level":"high","plddt":97.4634,"start":4,"end":127},{"cath_id":"3.20.20.120","chopping":"143-426","consensus_level":"high","plddt":97.2606,"start":143,"end":426}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09104","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09104-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09104-F1-predicted_aligned_error_v6.png","plddt_mean":97.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ENO2","jax_strain_url":"https://www.jax.org/strain/search?query=ENO2"},"sequence":{"accession":"P09104","fasta_url":"https://rest.uniprot.org/uniprotkb/P09104.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09104/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09104"}},"corpus_meta":[{"pmid":"6769532","id":"PMC_6769532","title":"Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase.","date":"1980","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/6769532","citation_count":204,"is_preprint":false},{"pmid":"30849967","id":"PMC_30849967","title":"The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30849967","citation_count":149,"is_preprint":false},{"pmid":"12909296","id":"PMC_12909296","title":"Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients.","date":"2003","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/12909296","citation_count":106,"is_preprint":false},{"pmid":"29247745","id":"PMC_29247745","title":"Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.","date":"2017","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29247745","citation_count":97,"is_preprint":false},{"pmid":"2201905","id":"PMC_2201905","title":"Multiple factors bind the upstream activation sites of the yeast enolase genes ENO1 and ENO2: ABFI protein, like repressor activator protein RAP1, binds cis-acting sequences which modulate repression or activation of transcription.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2201905","citation_count":95,"is_preprint":false},{"pmid":"17897967","id":"PMC_17897967","title":"Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17897967","citation_count":92,"is_preprint":false},{"pmid":"34709508","id":"PMC_34709508","title":"S100B, GFAP, UCH-L1 and NSE as predictors of abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy.","date":"2021","source":"Neurosurgical review","url":"https://pubmed.ncbi.nlm.nih.gov/34709508","citation_count":89,"is_preprint":false},{"pmid":"19047109","id":"PMC_19047109","title":"Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19047109","citation_count":86,"is_preprint":false},{"pmid":"19221293","id":"PMC_19221293","title":"NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children.","date":"2009","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19221293","citation_count":70,"is_preprint":false},{"pmid":"3537717","id":"PMC_3537717","title":"Identification of a regulatory region that mediates glucose-dependent induction of the Saccharomyces cerevisiae enolase gene ENO2.","date":"1986","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3537717","citation_count":69,"is_preprint":false},{"pmid":"29689546","id":"PMC_29689546","title":"ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29689546","citation_count":67,"is_preprint":false},{"pmid":"15619461","id":"PMC_15619461","title":"S100B and NSE serum levels in patients with Parkinson's disease.","date":"2005","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/15619461","citation_count":63,"is_preprint":false},{"pmid":"24795283","id":"PMC_24795283","title":"Combining NSE and S100B with clinical examination findings to predict survival after resuscitation from cardiac arrest.","date":"2014","source":"Resuscitation","url":"https://pubmed.ncbi.nlm.nih.gov/24795283","citation_count":60,"is_preprint":false},{"pmid":"38250157","id":"PMC_38250157","title":"Tumor-derived Exosomal ENO2 Modulates Polarization of Tumor-associated Macrophages through Reprogramming Glycolysis to Promote Progression of Diffuse Large B-cell Lymphoma.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38250157","citation_count":58,"is_preprint":false},{"pmid":"9506348","id":"PMC_9506348","title":"Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.","date":"1998","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9506348","citation_count":52,"is_preprint":false},{"pmid":"22185371","id":"PMC_22185371","title":"Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22185371","citation_count":51,"is_preprint":false},{"pmid":"18783450","id":"PMC_18783450","title":"Serum concentrations of s100b and NSE in migraine.","date":"2009","source":"Headache","url":"https://pubmed.ncbi.nlm.nih.gov/18783450","citation_count":50,"is_preprint":false},{"pmid":"25620024","id":"PMC_25620024","title":"ENO2 activity is required for the development and reproductive success of plants, and is feedback-repressed by AtMBP-1.","date":"2015","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25620024","citation_count":48,"is_preprint":false},{"pmid":"11467477","id":"PMC_11467477","title":"Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma.","date":"2001","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11467477","citation_count":48,"is_preprint":false},{"pmid":"19031951","id":"PMC_19031951","title":"ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.","date":"2008","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19031951","citation_count":46,"is_preprint":false},{"pmid":"36588153","id":"PMC_36588153","title":"Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer development.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36588153","citation_count":45,"is_preprint":false},{"pmid":"35256133","id":"PMC_35256133","title":"Electrochemical neuron-specific enolase (NSE) immunosensor based on CoFe2O4@Ag nanocomposite and AuNPs@MoS2/rGO.","date":"2022","source":"Analytica chimica acta","url":"https://pubmed.ncbi.nlm.nih.gov/35256133","citation_count":44,"is_preprint":false},{"pmid":"30423400","id":"PMC_30423400","title":"Diagnostic value of NT-proCNP compared to NSE and S100B in cerebrospinal fluid and plasma of patients with sepsis-associated encephalopathy.","date":"2018","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/30423400","citation_count":44,"is_preprint":false},{"pmid":"36945054","id":"PMC_36945054","title":"ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36945054","citation_count":42,"is_preprint":false},{"pmid":"30171330","id":"PMC_30171330","title":"Serial measurement of S100B and NSE in pediatric traumatic brain injury.","date":"2018","source":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/30171330","citation_count":38,"is_preprint":false},{"pmid":"35954207","id":"PMC_35954207","title":"ENO2 Promotes Colorectal Cancer Metastasis by Interacting with the LncRNA CYTOR and Activating YAP1-Induced EMT.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35954207","citation_count":37,"is_preprint":false},{"pmid":"37667133","id":"PMC_37667133","title":"ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy.","date":"2023","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37667133","citation_count":35,"is_preprint":false},{"pmid":"23796187","id":"PMC_23796187","title":"S100B and NSE as useful postmortem biochemical markers of traumatic brain injury in autopsy cases.","date":"2013","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/23796187","citation_count":34,"is_preprint":false},{"pmid":"7589398","id":"PMC_7589398","title":"Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1.","date":"1995","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/7589398","citation_count":34,"is_preprint":false},{"pmid":"33376560","id":"PMC_33376560","title":"The Combination of CA125 and NSE Is Useful for Predicting Liver Metastasis of Lung Cancer.","date":"2020","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/33376560","citation_count":33,"is_preprint":false},{"pmid":"24185583","id":"PMC_24185583","title":"CEA, SCC and NSE levels in exhaled breath condensate--possible markers for early detection of lung cancer.","date":"2013","source":"Journal of breath research","url":"https://pubmed.ncbi.nlm.nih.gov/24185583","citation_count":33,"is_preprint":false},{"pmid":"30214557","id":"PMC_30214557","title":"Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30214557","citation_count":33,"is_preprint":false},{"pmid":"16750933","id":"PMC_16750933","title":"S100B and NSE serum levels in obstructive sleep apnea syndrome.","date":"2006","source":"Sleep medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16750933","citation_count":32,"is_preprint":false},{"pmid":"8455635","id":"PMC_8455635","title":"A complex regulatory element from the yeast gene ENO2 modulates GCR1-dependent transcriptional activation.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8455635","citation_count":32,"is_preprint":false},{"pmid":"3587757","id":"PMC_3587757","title":"Localization of neuron-specific enolase (NSE) mRNA in human brain.","date":"1987","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/3587757","citation_count":32,"is_preprint":false},{"pmid":"22452413","id":"PMC_22452413","title":"Effects of hypothermia on NSE and S-100 protein levels in CSF in neonates following hypoxic/ischaemic brain damage.","date":"2012","source":"Acta paediatrica (Oslo, Norway : 1992)","url":"https://pubmed.ncbi.nlm.nih.gov/22452413","citation_count":32,"is_preprint":false},{"pmid":"22098917","id":"PMC_22098917","title":"Arsenic, cadmium and neuron specific enolase (ENO2, γ-enolase) expression in breast cancer.","date":"2011","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/22098917","citation_count":31,"is_preprint":false},{"pmid":"2350885","id":"PMC_2350885","title":"Ontogenic changes in expression of neuron-specific enolase (NSE) and its mRNA in the Purkinje cells of the rat cerebellum: immunohistochemical and in situ hybridization study.","date":"1990","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/2350885","citation_count":31,"is_preprint":false},{"pmid":"32792937","id":"PMC_32792937","title":"Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson's Disease.","date":"2020","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32792937","citation_count":30,"is_preprint":false},{"pmid":"36282321","id":"PMC_36282321","title":"Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.","date":"2023","source":"Laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36282321","citation_count":30,"is_preprint":false},{"pmid":"2249478","id":"PMC_2249478","title":"Localisation of neurone-specific enolase (ENO2) to 12p13.","date":"1990","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2249478","citation_count":28,"is_preprint":false},{"pmid":"24737292","id":"PMC_24737292","title":"Hypermethylation of the enolase gene (ENO2) in autism.","date":"2014","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/24737292","citation_count":27,"is_preprint":false},{"pmid":"33342344","id":"PMC_33342344","title":"IncRNA ZFAS1 contributes to the radioresistance of nasopharyngeal carcinoma cells by sponging hsa-miR-7-5p to upregulate ENO2.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/33342344","citation_count":27,"is_preprint":false},{"pmid":"25211554","id":"PMC_25211554","title":"Immunohistochemical investigation of S100 and NSE in cases of traumatic brain injury and its application for survival time determination.","date":"2015","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/25211554","citation_count":26,"is_preprint":false},{"pmid":"7917935","id":"PMC_7917935","title":"Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).","date":"1994","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7917935","citation_count":26,"is_preprint":false},{"pmid":"18617311","id":"PMC_18617311","title":"Serum concentration of NSE and S-100b during LVAD in non-resuscitated patients.","date":"2008","source":"Resuscitation","url":"https://pubmed.ncbi.nlm.nih.gov/18617311","citation_count":25,"is_preprint":false},{"pmid":"29244749","id":"PMC_29244749","title":"Serum Levels of S100b and NSE Proteins in Patients with Non-Transfusion-Dependent Thalassemia as Biomarkers of Brain Ischemia and Cerebral Vasculopathy.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29244749","citation_count":25,"is_preprint":false},{"pmid":"32871787","id":"PMC_32871787","title":"Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events.","date":"2020","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/32871787","citation_count":24,"is_preprint":false},{"pmid":"28352768","id":"PMC_28352768","title":"The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer.","date":"2016","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/28352768","citation_count":23,"is_preprint":false},{"pmid":"33180443","id":"PMC_33180443","title":"Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.","date":"2020","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/33180443","citation_count":23,"is_preprint":false},{"pmid":"21725169","id":"PMC_21725169","title":"Effect of endurance exercise training on the expression of GFAP, S100B, and NSE in the striatum of chronic/progressive mouse model of Parkinson's disease.","date":"2011","source":"NeuroRehabilitation","url":"https://pubmed.ncbi.nlm.nih.gov/21725169","citation_count":23,"is_preprint":false},{"pmid":"2201904","id":"PMC_2201904","title":"Sequences within an upstream activation site in the yeast enolase gene ENO2 modulate repression of ENO2 expression in strains carrying a null mutation in the positive regulatory gene GCR1.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2201904","citation_count":22,"is_preprint":false},{"pmid":"31191019","id":"PMC_31191019","title":"NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31191019","citation_count":21,"is_preprint":false},{"pmid":"17187827","id":"PMC_17187827","title":"Plasma S100beta and NSE levels and progression in multiple sclerosis.","date":"2006","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17187827","citation_count":21,"is_preprint":false},{"pmid":"18830828","id":"PMC_18830828","title":"Effects of neuregulin on expression of MMP-9 and NSE in brain of ischemia/reperfusion rat.","date":"2008","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/18830828","citation_count":20,"is_preprint":false},{"pmid":"36562383","id":"PMC_36562383","title":"ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment.","date":"2022","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/36562383","citation_count":18,"is_preprint":false},{"pmid":"32171903","id":"PMC_32171903","title":"Glial and neuronal markers in bipolar disorder: A meta-analysis testing S100B and NSE peripheral blood levels.","date":"2020","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32171903","citation_count":17,"is_preprint":false},{"pmid":"11985791","id":"PMC_11985791","title":"Enhanced expression of neuron-specific enolase (NSE) in pyothorax-associated lymphoma (PAL).","date":"2002","source":"Japanese journal of cancer research : Gann","url":"https://pubmed.ncbi.nlm.nih.gov/11985791","citation_count":17,"is_preprint":false},{"pmid":"35694066","id":"PMC_35694066","title":"Serum S100B and NSE Levels Correlate With Infarct Size and Bladder-Bowel Involvement Among Acute Ischemic Stroke Patients.","date":"2022","source":"Journal of neurosciences in rural practice","url":"https://pubmed.ncbi.nlm.nih.gov/35694066","citation_count":16,"is_preprint":false},{"pmid":"32024492","id":"PMC_32024492","title":"The effect of obstructive sleep apnea syndrome on serum S100B and NSE levels: a systematic review and meta-analysis of observational studies.","date":"2020","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32024492","citation_count":16,"is_preprint":false},{"pmid":"25202114","id":"PMC_25202114","title":"The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected].","date":"2014","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25202114","citation_count":16,"is_preprint":false},{"pmid":"9490097","id":"PMC_9490097","title":"S-100 and NSE as serum markers in melanoma.","date":"1997","source":"Acta oncologica (Stockholm, Sweden)","url":"https://pubmed.ncbi.nlm.nih.gov/9490097","citation_count":16,"is_preprint":false},{"pmid":"3101377","id":"PMC_3101377","title":"Immunohistochemical study of S-100 protein and neuron specific enolase (NSE) in melanocytes and the related tumors.","date":"1986","source":"Acta histochemica","url":"https://pubmed.ncbi.nlm.nih.gov/3101377","citation_count":16,"is_preprint":false},{"pmid":"4031972","id":"PMC_4031972","title":"Differentiation markers (S-100, GFAP, NSE and D2) in fetal rat brain cells during malignant transformation in cell culture.","date":"1985","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/4031972","citation_count":16,"is_preprint":false},{"pmid":"39061144","id":"PMC_39061144","title":"ENO2, a Glycolytic Enzyme, Contributes to Prostate Cancer Metastasis: A Systematic Review of Literature.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/39061144","citation_count":15,"is_preprint":false},{"pmid":"17650535","id":"PMC_17650535","title":"Brain injury markers (S100B and NSE) in chronic cocaine dependents.","date":"2007","source":"Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)","url":"https://pubmed.ncbi.nlm.nih.gov/17650535","citation_count":15,"is_preprint":false},{"pmid":"34721827","id":"PMC_34721827","title":"Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients.","date":"2021","source":"Journal of healthcare engineering","url":"https://pubmed.ncbi.nlm.nih.gov/34721827","citation_count":14,"is_preprint":false},{"pmid":"34790052","id":"PMC_34790052","title":"NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process.","date":"2021","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34790052","citation_count":14,"is_preprint":false},{"pmid":"12593474","id":"PMC_12593474","title":"Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.","date":"2003","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/12593474","citation_count":14,"is_preprint":false},{"pmid":"17110918","id":"PMC_17110918","title":"Fenretinide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells is associated with the differential expression of Hsp70, 14-3-3, pax-6, tubulin beta-III, NSE, and bag-1 proteins.","date":"2006","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/17110918","citation_count":14,"is_preprint":false},{"pmid":"28123815","id":"PMC_28123815","title":"The neonatal levels of TSB, NSE and CK-BB in autism spectrum disorder from Southern China.","date":"2016","source":"Translational neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28123815","citation_count":14,"is_preprint":false},{"pmid":"19471994","id":"PMC_19471994","title":"Comparison of S100B and NSE between cardiac surgery and interventional therapy for children.","date":"2009","source":"Pediatric cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19471994","citation_count":13,"is_preprint":false},{"pmid":"35356751","id":"PMC_35356751","title":"Reduced Concentrations of NSE, S100β, Aβ, and Proinflammatory Cytokines in Elderly Patients Receiving Ultrasound-Guided Combined Lumbar Plexus-Sciatic Nerve Block during Hip Replacement.","date":"2022","source":"Genetics research","url":"https://pubmed.ncbi.nlm.nih.gov/35356751","citation_count":13,"is_preprint":false},{"pmid":"19713034","id":"PMC_19713034","title":"p19(ras) Represses proliferation of non-small cell lung cancer possibly through interaction with Neuron-Specific Enolase (NSE).","date":"2009","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19713034","citation_count":13,"is_preprint":false},{"pmid":"32566576","id":"PMC_32566576","title":"Expression patterns and clinical significances of ENO2 in lung cancer: an analysis based on Oncomine database.","date":"2020","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32566576","citation_count":12,"is_preprint":false},{"pmid":"35621141","id":"PMC_35621141","title":"E2F1 promotes Warburg effect and cancer progression via upregulating ENO2 expression in Ewing sarcoma.","date":"2022","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/35621141","citation_count":12,"is_preprint":false},{"pmid":"38292901","id":"PMC_38292901","title":"Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury.","date":"2024","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38292901","citation_count":12,"is_preprint":false},{"pmid":"32724442","id":"PMC_32724442","title":"Correlation of changes in serum S100β, NSE and inflammatory factor levels with MMSE and MoCA in intracranial tumor patients with cognitive impairment.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32724442","citation_count":12,"is_preprint":false},{"pmid":"21535942","id":"PMC_21535942","title":"Experimental subacute spinal cord compression: correlation of serial S100B and NSE serum measurements, histopathological changes, and outcome.","date":"2011","source":"Neurological research","url":"https://pubmed.ncbi.nlm.nih.gov/21535942","citation_count":12,"is_preprint":false},{"pmid":"31202897","id":"PMC_31202897","title":"SIRT 1 binding with PKM and NSE and modulate their acetylation and activities.","date":"2019","source":"Biochimica et biophysica acta. Proteins and proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/31202897","citation_count":11,"is_preprint":false},{"pmid":"35368891","id":"PMC_35368891","title":"Application Value of Serum TK1 and PCDGF, CYFRA21-1, NSE, and CEA plus Enhanced CT Scan in the Diagnosis of Nonsmall Cell Lung Cancer and Chemotherapy Monitoring.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35368891","citation_count":11,"is_preprint":false},{"pmid":"32782515","id":"PMC_32782515","title":"Sodium valproate combined with levetiracetam in pediatric epilepsy and its influence on NSE, IL-6, hs-CRP and electroencephalogram improvement.","date":"2020","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32782515","citation_count":11,"is_preprint":false},{"pmid":"24307347","id":"PMC_24307347","title":"NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus.","date":"2013","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24307347","citation_count":11,"is_preprint":false},{"pmid":"3420027","id":"PMC_3420027","title":"S-100 protein and neuron specific enolase (NSE) expression by chordomas in relation to the composition of their stromal mucosubstances.","date":"1988","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/3420027","citation_count":11,"is_preprint":false},{"pmid":"34350711","id":"PMC_34350711","title":"Overexpression of let-7d explains down-regulated KDM3A and ENO2 in the pathogenesis of preeclampsia.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34350711","citation_count":9,"is_preprint":false},{"pmid":"26124190","id":"PMC_26124190","title":"Elevated Serum Levels of NSE and S-100β Correlate with Increased Risk of Acute Cerebral Infarction in Asian Populations.","date":"2015","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/26124190","citation_count":9,"is_preprint":false},{"pmid":"21743141","id":"PMC_21743141","title":"Serum concentrations of NSE and S100B in spinocerebellar ataxia type 3/Machado-Joseph disease.","date":"2011","source":"Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21743141","citation_count":9,"is_preprint":false},{"pmid":"37760940","id":"PMC_37760940","title":"ENO2 as a Biomarker Regulating Energy Metabolism to Promote Tumor Progression in Clear Cell Renal Cell Carcinoma.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/37760940","citation_count":8,"is_preprint":false},{"pmid":"35366826","id":"PMC_35366826","title":"Based on multiple machine learning to identify the ENO2 as diagnosis biomarkers of glaucoma.","date":"2022","source":"BMC ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/35366826","citation_count":8,"is_preprint":false},{"pmid":"36447551","id":"PMC_36447551","title":"GFAP and Neuron Specific Enolase (NSE) in the Serum of Suicide Attempters.","date":"2022","source":"Medical journal of the Islamic Republic of Iran","url":"https://pubmed.ncbi.nlm.nih.gov/36447551","citation_count":8,"is_preprint":false},{"pmid":"39462073","id":"PMC_39462073","title":"NSE and S100β as serum alarmins in predicting neurological outcomes after cardiac arrest.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39462073","citation_count":8,"is_preprint":false},{"pmid":"37203842","id":"PMC_37203842","title":"Correlation between HRCT signs and levels of CA125, SCCA, and NSE for different pathological types of lung cancer.","date":"2023","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37203842","citation_count":8,"is_preprint":false},{"pmid":"33317735","id":"PMC_33317735","title":"Serum NO, S100B, NSE concentrations in migraine and their relationship.","date":"2020","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/33317735","citation_count":8,"is_preprint":false},{"pmid":"38203674","id":"PMC_38203674","title":"Concordance between the In Vivo Content of Neurospecific Proteins (BDNF, NSE, VILIP-1, S100B) in the Hippocampus and Blood in Patients with Epilepsy.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38203674","citation_count":8,"is_preprint":false},{"pmid":"29077174","id":"PMC_29077174","title":"Clinical significance of dynamic measurements of seric TNF-α, HMGBl, and NSE levels and aEEG monitoring in neonatal asphyxia.","date":"2017","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29077174","citation_count":8,"is_preprint":false},{"pmid":"8386493","id":"PMC_8386493","title":"Soluble interleukin-2 receptors (sIL-2R) and neuron specific enolase (NSE) in small cell lung carcinoma.","date":"1993","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8386493","citation_count":8,"is_preprint":false},{"pmid":"21159242","id":"PMC_21159242","title":"[Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].","date":"2010","source":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21159242","citation_count":7,"is_preprint":false},{"pmid":"38235879","id":"PMC_38235879","title":"Effects of parecoxib on postoperative cognitive dysfunction and serum levels of NSE and S100β in elderly patients undergoing surgery.","date":"2024","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38235879","citation_count":7,"is_preprint":false},{"pmid":"39854009","id":"PMC_39854009","title":"ENO2-Regulated Glycolysis in Endothelial Cells Contributes to FGF2-Induced Retinal Neovascularization.","date":"2025","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/39854009","citation_count":7,"is_preprint":false},{"pmid":"37194201","id":"PMC_37194201","title":"Relationships of serum VILIP-1, NSE, and ADP levels with postoperative cognitive dysfunction in elderly patients undergoing general anesthesia: a retrospective, observational study.","date":"2023","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/37194201","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53649,"output_tokens":5802,"usd":0.123989,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14534,"output_tokens":4359,"usd":0.090823,"stage2_stop_reason":"end_turn"},"total_usd":0.214812,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1980,\n      \"finding\": \"Neuron-specific enolase (NSE/ENO2) is expressed specifically in neurons (not glial cells) of mature brain, with levels very low in embryonic brain and increasing coincident with morphological and functional neuronal maturation, consistent with a developmental switch from non-neuronal enolase (NNE/ENO1) to NSE during neuronal differentiation.\",\n      \"method\": \"Radioimmunoassay of isoenzyme content during rat brain development, with regional and temporal profiling\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative isoenzyme measurement across developmental stages, single lab but systematic temporal and regional analysis\",\n      \"pmids\": [\"6769532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"In yeast, ENO2 contains two upstream activation site (UAS) cis-acting regulatory regions immediately flanking position 461 bp upstream of the transcriptional initiation site; either UAS alone is sufficient for glucose-dependent induction and normal expression on gluconeogenic carbon sources, but deletion of both abolishes expression. Small deletions within the UAS permit normal expression on gluconeogenic sources but abolish glucose-dependent induction, identifying a specific cis-acting sequence mediating glucose induction.\",\n      \"method\": \"Deletion mapping of ENO2 5' flanking sequences fused to ENO1 coding sequences; integration at ENO1 locus; expression monitored on glucose vs. gluconeogenic carbon sources\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vivo deletion mapping with multiple mutant constructs and orthogonal carbon source conditions, replicated across multiple deletion alleles\",\n      \"pmids\": [\"3537717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Three distinct protein-binding sites exist within the upstream activation sites of yeast ENO2: RAP1 protein binds sequences overlapping UAS1; ABFI (autonomously replicating sequence-binding factor) binds sequences within the UAS2 element; and EBF1 (enolase-binding factor) binds sequences overlapping UAS2 of ENO1. The ABFI-binding site in ENO2 overlaps sequences required for UAS2 activity and for repression of ENO2 in gcr1 null mutants, indicating ABFI, like RAP1, can mediate both positive and negative regulation.\",\n      \"method\": \"DNase I footprinting, gel mobility shift assays, deletion analysis in vivo, identification of RAP1 and ABFI by protein purification and binding\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical and genetic methods (footprinting, EMSA, in vivo expression) in single rigorous study\",\n      \"pmids\": [\"2201905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"In yeast, ABFI is identified as the major protein binding the UAS/repression site of ENO2; deletion of this site permits wild-type ENO2 expression in gcr1 null strains, demonstrating that ABFI-bound sequences are required both for transcriptional activation in wild-type and for GCR1-dependent repression; the UAS/repression site alone is sufficient for transcriptional activation but not sufficient for repression in gcr1 backgrounds.\",\n      \"method\": \"Deletion mapping in gcr1 null strains, gel mobility shift assays identifying ABFI, in vivo transcription assays with UAS-less promoter cassettes\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic epistasis (gcr1 null) combined with protein-DNA binding identification and in vivo transcription assays\",\n      \"pmids\": [\"2201904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Human ENO2 gene localizes to chromosome region 12p13, as determined by in situ hybridization; additional minor hybridization to 1p36 likely reflects cross-hybridization to ENO1, and a signal at chromosome 17 may represent another enolase family member.\",\n      \"method\": \"In situ hybridization of human ENO2 cDNA to chromosomes\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, single method (in situ hybridization), no functional validation\",\n      \"pmids\": [\"2249478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"NSE immunoreactivity and NSE mRNA both increase in rat cerebellar Purkinje cells from postnatal day 3 to 9, but thereafter NSE-immunoreactive Purkinje cell somata decrease in number while mRNA remains detectable in somata through adulthood, with distinct NSE immunoreactivity remaining in Purkinje cell axons. This discrepancy suggests negative translational control and/or axoplasmic transport of NSE protein.\",\n      \"method\": \"Immunohistochemistry and in situ hybridization in rat cerebellum across postnatal development\",\n      \"journal\": \"Brain research. Developmental brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (IHC and ISH) systematically applied across developmental time points, single lab\",\n      \"pmids\": [\"2350885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"NSE mRNA is expressed specifically in neurons (not glia or liver cells) in human brain, as detected by in situ hybridization with probes from the 3' untranslated region of ENO2 in autopsy brain samples from controls and Alzheimer's disease patients.\",\n      \"method\": \"In situ hybridization with biotinylated DNA and RNA probes in human autopsy brain tissue\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single method (ISH), single lab, no functional manipulation\",\n      \"pmids\": [\"3587757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A 60-bp ENO2 sequence is sufficient to confer high-level, GCR1-dependent transcriptional activation; it can be subdivided into a 30-bp region containing overlapping RAP1 and GCR1 binding sites (not sufficient alone for activation) and a 30-bp region with a novel GCR1-independent enhancer element. The overlapping ABFI/RAP1 sites upstream function together with the GCR1/RAP1-binding sequences to stage transcriptional activation.\",\n      \"method\": \"Enhancerless CYC1 promoter fusion assay, deletion mapping, in vivo transcription quantification in gcr1 null strains\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic epistasis with gcr1 null, multiple deletion constructs, in vivo expression assays with heterologous promoter system\",\n      \"pmids\": [\"8455635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"p19(ras), an alternative splicing product of c-H-ras, physically interacts with NSE (ENO2) and inhibits its enzymatic activity; co-immunoprecipitation confirmed the interaction both endogenously and in overexpression systems; p19(ras) also inhibits enolase alpha activity in vitro. The interaction suppresses lung cancer cell proliferation that was increased by NSE.\",\n      \"method\": \"Yeast two-hybrid identification of NSE as p19(ras)-binding partner; co-immunoprecipitation in endogenous and overexpression systems; in vitro enzymatic activity assay; cell proliferation assay in H1299 cells\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus in vitro activity assay plus cell proliferation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19713034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ENO2 (NSE) is upregulated in GBM cells under cellular stress conditions (serum starvation and hypoxia); NSE knockdown by siRNA reduces GBM cell migration and sensitizes cells to hypoxia, radiotherapy, and temozolomide, establishing a functional role for ENO2 in stress adaptation and resistance in glioblastoma cells.\",\n      \"method\": \"qPCR under different culture conditions; siRNA knockdown of NSE; Electric cell-substrate impedance sensing (ECIS) for migration; MTS viability assay after irradiation and temozolomide\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean siRNA knockdown with multiple phenotypic readouts (migration, viability, drug sensitivity), single lab\",\n      \"pmids\": [\"22185371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ENO2 (NSE) expressed in MCF-10A breast epithelial cells transformed by arsenite (As+3) or cadmium (Cd+2) localizes to both cytoplasm and nucleus, whereas ENO1 localizes only to cytoplasm; cytoplasmic ENO2 co-localizes with ENO1. Both acute and chronic exposure to As+3 or Cd+2 significantly induces ENO2 expression with no effect on ENO1 expression.\",\n      \"method\": \"Immunofluorescence localization; Western blot; acute and chronic metal exposure of MCF-10A cells\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single set of methods, localization shown but functional consequence of nuclear ENO2 not established\",\n      \"pmids\": [\"22098917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ENO2 promotes ALL cell growth, glycolysis, and glucocorticoid resistance; mechanistically, ENO2 upregulates glycolysis-related genes and enhances AKT activity with subsequent GSK-3β phosphorylation, inducing cell proliferation and glycolysis. Silencing ENO2 with shRNAs inhibits these effects, and combined ENO2 silencing plus 2-deoxyglucose synergistically inhibits leukemia cell survival.\",\n      \"method\": \"shRNA knockdown; Cell Counting Kit-8 proliferation assay; glucose consumption assay; Western blotting; in vivo tumorigenesis in NOD/SCID mice\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA knockdown with multiple orthogonal readouts (proliferation, glycolysis, in vivo), single lab\",\n      \"pmids\": [\"29689546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NSE (ENO2) from DLBCL lymphoma cells is transferred to macrophages via exosomes, whereupon NSE enhances nuclear p50 translocation and suppresses classical NF-κB activity in macrophages, promoting M2 polarization and migration of macrophages, thereby promoting lymphoma progression in vitro and in vivo.\",\n      \"method\": \"Functional overexpression/knockdown studies in lymphoma cell lines; exosome isolation; macrophage co-culture; in vitro and in vivo (mouse) experiments; Western blotting for p50 nuclear translocation\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway (NF-κB) identified with nuclear translocation assay plus in vivo validation, single lab\",\n      \"pmids\": [\"31191019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SIRT1 physically binds NSE (ENO2) and PKM in rat brain tissue; modulation of SIRT1 enzymatic activity (by agonist SRT1720 or antagonist EX527, or by SIRT1 overexpression/knockout) significantly affects the acetylation level of endogenous NSE, and changes in NSE acetylation affect its catalytic glycolytic activity.\",\n      \"method\": \"GST pull-down followed by LC-MS/MS identification; co-immunoprecipitation; SIRT1 agonist/antagonist treatment; SIRT1 overexpression and knockout; measurement of NSE catalytic activity\",\n      \"journal\": \"Biochimica et biophysica acta. Proteins and proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pull-down + Co-IP + functional activity assay + genetic manipulation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31202897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ENO2 promotes cell proliferation and glycolysis in HNSCC partially by controlling PKM2 protein stability and nuclear translocation: loss of ENO2 promotes PKM2 degradation via the ubiquitin-proteasome pathway and prevents nuclear translocation of PKM2 by inactivating AKT signaling, blocking PKM2-mediated glycolytic flux and CCND1-associated cell cycle progression.\",\n      \"method\": \"qRT-PCR, Western blotting, immunofluorescence, immunoprecipitation, ChIP-PCR, ATP and glucose level assays; ENO2 inhibitor AP-III-a4 in preclinical mouse model\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (IP, ChIP, IHC, metabolic assays, in vivo), single lab\",\n      \"pmids\": [\"36588153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ENO2 promotes colorectal cancer cell migration and invasion through interaction with lncRNA CYTOR; this interaction does not depend on glycolysis regulation. CYTOR mediates ENO2 binding to LATS1, competitively inhibiting YAP1 phosphorylation and triggering epithelial-mesenchymal transition (EMT).\",\n      \"method\": \"ENO2 knockdown and overexpression; migration/invasion assays; co-immunoprecipitation of ENO2-CYTOR-LATS1 complex; YAP1 phosphorylation analysis; TCGA/GEO database analysis; 184 local CRC samples\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrating three-component complex, loss/gain of function with phenotypic readouts, single lab\",\n      \"pmids\": [\"35954207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ENO2-derived metabolite phosphoenolpyruvate (PEP) selectively inhibits HDAC1 activity, increasing acetylation of β-catenin and activating the β-catenin pathway in colorectal cancer, driving resistance to antiangiogenic therapy. ENO2 overexpression induces neuroendocrine differentiation and promotes malignant behavior; ENO2 inhibitors (AP-III-a4 or POMHEX) synergize with antiangiogenic drugs in vitro and in drug-resistant CRC xenograft mouse models.\",\n      \"method\": \"CRC mouse models and human participant samples; in vitro HDAC1 activity assay with PEP; β-catenin acetylation and pathway analysis; ENO2 inhibitor treatment in vivo\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic assay demonstrating PEP inhibits HDAC1, combined with in vivo mouse models and human participant data, multiple orthogonal methods\",\n      \"pmids\": [\"37667133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ENO2 and ALDOC are required for anchorage-independent 3D tumor spheroid growth across lung and breast cancer cell lines; siRNA-mediated knockdown of ENO2 significantly reduces lactate production, viability, and spheroid size in H460, HCC827, MCF7, and T47D cell lines, demonstrating that ENO2-driven glycolytic flux supports anchorage-independent survival.\",\n      \"method\": \"siRNA knockdown; multi-omics (transcriptomics, proteomics, metabolomics); lactate production assay; viability and spheroid size measurement in 3D culture\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown across four cell lines with metabolic and viability readouts, multi-omics validation, single lab\",\n      \"pmids\": [\"36945054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DLBCL-derived exosomal ENO2 is assimilated by macrophages and modulates macrophage polarization (increased M2, decreased M1) through reprogramming glycolysis via the GSK3β/β-catenin/c-Myc signaling pathway, thereby promoting DLBCL cell proliferation, migration, and invasion in vitro and in vivo.\",\n      \"method\": \"Exosome isolation and uptake assays; in vitro and in vivo macrophage polarization experiments; pathway inhibition assays; bioinformatics analysis\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — exosome uptake demonstrated with in vitro and in vivo validation, pathway mechanistic dissection, single lab\",\n      \"pmids\": [\"38250157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ENO2 expression in trophoblasts is regulated epigenetically: the histone demethylase KDM3A binds the ENO2 locus and reduces its methylation, promoting ENO2 expression; let-7d miRNA directly targets KDM3A to suppress it, resulting in increased ENO2 methylation and reduced ENO2 expression. Overexpression of let-7d suppresses trophoblast proliferation, migration, and invasion, which can be rescued by restoring ENO2 expression.\",\n      \"method\": \"Dual luciferase reporter assay for let-7d/KDM3A and let-7d/ENO2 interactions; ChIP experiment identifying KDM3A methylation of ENO2 locus; gain/loss-of-function; in vivo PE rat model\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for epigenetic regulation + luciferase reporter + in vivo rat model, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"34350711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"E2F1 transcription factor upregulates ENO2 expression to promote the Warburg effect (increased glucose uptake, lactate production, ATP generation) and cell viability and invasion in Ewing sarcoma; altering E2F1 expression correspondingly changes ENO2 levels and aerobic glycolysis.\",\n      \"method\": \"E2F1 overexpression/knockdown; glucose uptake, lactate production, ATP generation assays; cell viability and invasion assays\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, indirect evidence that E2F1 regulates ENO2, mechanism of transcriptional regulation not directly demonstrated (no ChIP or promoter assay shown)\",\n      \"pmids\": [\"35621141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FGF2 stimulation of human retinal microvascular endothelial cells upregulates ENO2 protein levels and glycolytic activity; ENO2 knockdown diminishes glycolytic activity and impairs angiogenic processes (tube formation, migration, proliferation). The ENO2 inhibitor AP-III-a4 alleviates retinal neovascularization in the oxygen-induced retinopathy mouse model in vivo.\",\n      \"method\": \"Data-independent acquisition proteomics; qRT-PCR and Western blot; siRNA knockdown; transwell/EdU/tube formation assays; ENO2 inhibitor treatment in OIR mouse model; immunofluorescence\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics + knockdown + in vivo inhibitor, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"39854009\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ENO2 (NSE) is a neuron-specific glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate (PEP); beyond glycolysis, ENO2-derived PEP functions as an endogenous inhibitor of HDAC1 to activate β-catenin signaling, ENO2 controls PKM2 stability and nuclear translocation via AKT-ubiquitin pathways, it is deacetylated and regulated by SIRT1, it can be transferred via exosomes to reprogram macrophage polarization through NF-κB and GSK3β/β-catenin/c-Myc pathways, its expression is regulated by transcription factors RAP1/ABFI/GCR1 (in yeast) and by epigenetic methylation via the let-7d/KDM3A axis (in mammals), and its activity is inhibited by physical interaction with p19(ras).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ENO2 (neuron-specific enolase, NSE) is a glycolytic enzyme whose expression switches on during neuronal maturation, replacing the non-neuronal isoform as neurons morphologically and functionally differentiate [#0, #6]. Beyond its housekeeping role in catalyzing 2-phosphoglycerate to phosphoenolpyruvate (PEP), ENO2 functions as a driver of aerobic glycolysis (the Warburg effect) that supports proliferation, migration, and stress adaptation across diverse cancers, including glioblastoma, acute lymphoblastic leukemia, head and neck and colorectal carcinomas, and in 3D anchorage-independent growth [#9, #11, #14, #17]. A key non-canonical mechanism is metabolite-mediated signaling: ENO2-derived PEP selectively inhibits HDAC1, increasing β-catenin acetylation and activating β-catenin signaling to drive neuroendocrine differentiation and antiangiogenic therapy resistance [#16]. ENO2 additionally couples to AKT/GSK-3β signaling to promote glycolysis and glucocorticoid resistance, and controls PKM2 protein stability and nuclear translocation via the ubiquitin-proteasome and AKT pathways, linking it to CCND1-associated cell cycle progression [#11, #14]. Through protein and RNA interactions ENO2 also acts independently of its catalytic function—binding lncRNA CYTOR and LATS1 to inhibit YAP1 phosphorylation and trigger EMT [#15]—and can be exported in exosomes to reprogram macrophage polarization toward an M2 state via NF-κB and GSK3β/β-catenin/c-Myc pathways [#12, #18]. ENO2 enzymatic activity is regulated post-translationally by SIRT1-dependent deacetylation [#13] and inhibited by physical interaction with the c-H-ras splice product p19(ras) [#8]. Its expression is controlled transcriptionally and epigenetically—by the let-7d/KDM3A demethylation axis in trophoblasts [#19] and, in yeast, by RAP1/ABFI/GCR1 acting through defined upstream activation sites [#1, #2, #7].\",\n  \"teleology\": [\n    {\n      \"year\": 1980,\n      \"claim\": \"Established that ENO2 is the neuronally-restricted enolase isoform whose induction tracks neuronal differentiation, defining it as a maturation marker distinct from the non-neuronal isoform.\",\n      \"evidence\": \"Radioimmunoassay of enolase isoenzymes across rat brain development with regional/temporal profiling, confirmed by in situ hybridization in human brain\",\n      \"pmids\": [\"6769532\", \"3587757\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish the molecular trigger of the NNE-to-NSE switch\", \"Functional consequence of neuron-restricted expression not addressed\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Dissected the cis- and trans-regulatory logic of yeast ENO2 transcription, showing overlapping RAP1/ABFI/GCR1 binding sites within upstream activation sequences mediate both glucose-dependent activation and GCR1-dependent repression.\",\n      \"evidence\": \"Deletion mapping of 5' flanking sequences, DNase I footprinting, EMSA, and in vivo expression assays in gcr1 null strains on glucose vs. gluconeogenic carbon sources\",\n      \"pmids\": [\"3537717\", \"2201905\", \"2201904\", \"8455635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulatory logic established in yeast, not mapped to mammalian ENO2 promoter\", \"Does not connect transcriptional control to enzyme function\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified the first physical regulator of mammalian ENO2 activity, showing p19(ras) binds and inhibits NSE enzymatic activity to suppress tumor cell proliferation.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal co-immunoprecipitation (endogenous and overexpression), in vitro enzyme activity assay, and proliferation assays in H1299 cells\",\n      \"pmids\": [\"19713034\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the inhibitory interaction not defined\", \"Physiological contexts where p19(ras) regulates ENO2 not established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated a functional pro-survival role for ENO2 in cancer, linking its stress-induced upregulation to migration and therapy resistance.\",\n      \"evidence\": \"siRNA knockdown in glioblastoma cells with migration, viability, and drug/radiation sensitivity readouts under hypoxia and serum starvation; nuclear/cytoplasmic localization in transformed breast epithelial cells\",\n      \"pmids\": [\"22185371\", \"22098917\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking ENO2 to resistance not resolved at this stage\", \"Functional significance of nuclear ENO2 localization not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected ENO2 to oncogenic signaling, showing it activates AKT/GSK-3β to drive glycolysis, proliferation, and glucocorticoid resistance.\",\n      \"evidence\": \"shRNA knockdown, proliferation and glucose consumption assays, Western blotting, and in vivo tumorigenesis in NOD/SCID mice, with 2-deoxyglucose combination\",\n      \"pmids\": [\"29689546\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ENO2 acts on AKT signaling enzymatically or non-enzymatically not distinguished\", \"Direct AKT-pathway interaction partner not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed ENO2 as both a post-translationally regulated enzyme and an intercellular signaling molecule—deacetylated by SIRT1 to control catalytic activity, and exported via exosomes to reprogram macrophages through NF-κB.\",\n      \"evidence\": \"GST pull-down/LC-MS/MS and Co-IP for SIRT1 binding with acetylation and activity assays; exosome isolation, macrophage co-culture, and p50 nuclear translocation assays in lymphoma models in vitro and in vivo\",\n      \"pmids\": [\"31202897\", \"31191019\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific acetylated lysine residues controlling activity not mapped\", \"Mechanism of ENO2 packaging into exosomes unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined an epigenetic regulatory axis controlling ENO2 expression, with KDM3A demethylating the locus to activate it and let-7d suppressing KDM3A to silence it.\",\n      \"evidence\": \"Dual luciferase reporter assays, ChIP for KDM3A at the ENO2 locus, gain/loss-of-function, and an in vivo preeclampsia rat model in trophoblasts\",\n      \"pmids\": [\"34350711\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this axis operates outside trophoblasts not tested\", \"Direct demethylase enzymatic action on ENO2 chromatin not biochemically isolated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Uncovered a glycolysis-independent function of ENO2 in metastasis, acting as a scaffold with lncRNA CYTOR and LATS1 to inhibit YAP1 phosphorylation and drive EMT.\",\n      \"evidence\": \"Knockdown/overexpression with migration/invasion assays, Co-IP of the ENO2-CYTOR-LATS1 complex, YAP1 phosphorylation analysis, and clinical CRC sample correlation\",\n      \"pmids\": [\"35954207\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the ternary complex not resolved\", \"Whether RNA binding is direct or bridged by other factors unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established the landmark non-canonical mechanism in which ENO2's metabolic product PEP acts as an endogenous HDAC1 inhibitor to activate β-catenin and drive neuroendocrine differentiation and therapy resistance, while confirming ENO2-driven glycolytic flux sustains anchorage-independent tumor growth.\",\n      \"evidence\": \"In vitro HDAC1 activity assay with PEP, β-catenin acetylation/pathway analysis, ENO2 inhibitor treatment in drug-resistant CRC xenografts and human samples; siRNA knockdown across four lung/breast lines with lactate and spheroid readouts\",\n      \"pmids\": [\"37667133\", \"36945054\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative threshold of PEP needed to inhibit HDAC1 in vivo not defined\", \"Whether PEP-HDAC1 inhibition operates in non-malignant neurons unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Refined the exosomal mechanism, showing transferred ENO2 reprograms macrophage glycolysis via the GSK3β/β-catenin/c-Myc pathway to promote M2 polarization and tumor progression.\",\n      \"evidence\": \"Exosome uptake assays, in vitro and in vivo macrophage polarization, pathway inhibition, and bioinformatics in DLBCL\",\n      \"pmids\": [\"38250157\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether transferred ENO2 acts enzymatically or as a signaling protein in recipient macrophages not resolved\", \"Receptor/uptake route for ENO2-bearing exosomes unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended ENO2's glycolytic-angiogenic role beyond cancer, showing FGF2-induced ENO2 supports endothelial glycolysis and pathological retinal neovascularization.\",\n      \"evidence\": \"DIA proteomics, siRNA knockdown, tube formation/migration/proliferation assays, and ENO2 inhibitor (AP-III-a4) in the oxygen-induced retinopathy mouse model\",\n      \"pmids\": [\"39854009\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking FGF2 signaling to ENO2 induction not defined\", \"Whether the PEP-HDAC1 axis contributes to angiogenesis not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ENO2's canonical glycolytic catalysis, its moonlighting metabolite-signaling (PEP-HDAC1), and its non-enzymatic scaffolding/exosomal roles are coordinated within a single cell—and whether these mechanisms operate in its native neuronal context—remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model integrating catalytic and non-catalytic functions\", \"Native neuronal function beyond being a differentiation marker uncharacterized\", \"No Mendelian disease link established in the corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016829\", \"supporting_discovery_ids\": [16, 17]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [11, 16, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 14, 15, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 11, 14, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PKM2\", \"SIRT1\", \"p19(ras)\", \"LATS1\", \"CYTOR\", \"HDAC1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}